To systematically examine the synergistic mechanisms underlying the combined contribution of hypertension and dyslipidemia to cardiovascular disease (CVD) progression.
Approach:
Key Findings:
Hypertension and dyslipidemia form a positive feedback loop that amplifies vascular inflammation and metabolic dysregulation.
The interplay of these conditions disrupts endothelial function, increases oxidative stress, and promotes chronic inflammation.
Interpretation:
The review emphasizes the need for a precision medicine framework that addresses the synergistic pathophysiology of hypertension and dyslipidemia.
Limitations:
Current clinical management primarily relies on pharmacological interventions, which may yield suboptimal efficacy.
Single-target therapies are often limited by side effects, drug resistance, and poor long-term adherence.
Conclusion:
A shift towards integrated, pathophysiology-based interventions is necessary for managing cardiovascular comorbidities effectively.
